A 36-week Turkish clinic study comparing three GLP-1 receptor agonists in 200+ non-diabetic adults with overweight or obesity found tirzepatide delivered superior weight loss compared to both semaglutide and liraglutide. All three medications produced significant weight reduction and waist circumference improvements, with tirzepatide also showing greater triglyceride reduction benefits. This real-world evidence fills a critical gap beyond controlled trials, demonstrating how these increasingly popular weight-loss medications perform in routine clinical practice. The findings align with tirzepatide's dual GLP-1/GIP receptor mechanism potentially offering enhanced metabolic benefits over single-target approaches. However, the single-center design and Turkish population limit broader generalizability, while the 36-week timeframe doesn't capture long-term sustainability or rare adverse events. Most significantly, this confirms tirzepatide's clinical superiority isn't just a trial artifact—it translates to meaningful real-world advantages. With obesity rates climbing globally and these medications becoming mainstream weight management tools, understanding their comparative effectiveness helps clinicians optimize treatment selection for the growing population seeking pharmaceutical weight loss interventions.